AstraZeneca to showcase transformative data across diverse pipeline at World Conference on Lung Cancer
Data for datopotamab deruxtecan (DS-1062) and Enhertu signal strong potential of these antibody drug conjugates in advanced lung cancer New non-small cell lung cancer data for Tagrisso and Imfinzi further demonstrate the impact of treating patients in early stages of the diseaseAstraZeneca will present new data from across the innovative lung cancer portfolio at the IASLC 2020 World Conference on Lung Cancer (WCLC), hosted by the International Association for the Study of Lung Cancer, 28 to 31 January 2021. Eleven AstraZeneca medicines and potential new medicines from the pipeline